Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Polyclonal Antibody Against Different Extracellular Subdomains of Her2 Induces Tumor Growth Inhibition in Vitro Pubmed



Hosseinighatar R1 ; Soltantoyeh T1 ; Bahadori M2 ; Khoshnoodi J1 ; Golsazshirazi F1 ; Jedditehrani M2 ; Amiri MM1 ; Shokri F1, 2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Iran
  2. 2. Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran

Source: Iranian Journal of Immunology Published:2017


Abstract

Background: Human epidermal growth factor receptor 2 (HER2) has a crucial role in several malignancies. The extracellular domain of HER2 (HER2-ECD) has been extensively employed as an important target in passive and active immunotherapy. Isolated recombinant prokaryotic HER2-ECD subdomains were previously found to be ineffective in inducing anti-tumor antibody response. Objective: To employ recombinant eukaryotic HER2-ECD subdomains to raise anti-HER2 antibodies and determine their anti-tumor activity in vitro. Methods: Two paired subdomains of HER2-ECD (DI+II and DIII+IV), representing Pertuzumab and Trastuzumab binding domains, respectively, along with the full extracellular domain of HER2 were generated in CHO-K1 cells. Polyclonal antibodies were raised against these subdomains and characterized using ELISA, flow cytometry, and immunoblot and their anti-tumor activity was assessed by XTT assay. The cross-reactivity of these antibodies was specified along with other members of the human HER family. Results: Similar to Trastuzumab and anti-HER2-ECD antibody, anti-DI+II and DIII+IV polyclonal antibodies reacted with recombinant HER2-ECD and native HER2 expressed on tumor cells. These two polyclonal antibodies were able to inhibit the binding of Pertuzumab and Trastuzumab to HER2, respectively, and did not cross-react with other members of HER family. These antibodies were able to inhibit tumor cell growth in vitro, similar to Trastuzumab. Conclusion: The high immunogenicity of human HER2 DI+II and DIII+IV subdomains in rabbits and the tumor inhibitory activity of the purified specific antibodies imply that they might be suitable for active immunotherapy in formulation with appropriate adjuvants and in combination with other HER2 specific therapeutics. © 2017, Shiraz University of Medical Sciences. All rights reserved.
Related Docs
View other Related Docs
1. Epitope Mapping of Human Her2 Specific Mouse Monoclonal Antibodies Using Recombinant Extracellular Subdomains, Asian Pacific Journal of Cancer Prevention (2017)
2. Differential Effects of Inhibitory and Stimulatory Anti-Her2 Monoclonal Antibodies on Akt/Erk Signaling Pathways, Asian Pacific Journal of Cancer Prevention (2018)
3. Immunization With Her2 Extracellular Subdomain Proteins Induces Cellular Response and Tumor Growth Inhibition in Mice, Immunotherapy (2018)
4. Potent Anti-Tumor Immune Response and Tumor Growth Inhibition Induced by Her2 Subdomain Fusion Protein in a Mouse Tumor Model, Journal of Cancer Research and Clinical Oncology (2023)
5. Antibody Response to Human Extracellular Her2 Subdomain Proteins in Mice, Iranian Journal of Immunology (2017)
6. Antibody Response to Her2 Extracellular Domain and Subdomains in Mouse Following Dna Immunization, Tumor Biology (2016)
7. Monoclonal Antibodies for Cancer Immunotherapy, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)
8. Hersintuzumab: A Novel Humanized Anti-Her2 Monoclonal Antibody Induces Potent Tumor Growth Inhibition, Investigational New Drugs (2018)
Experts (# of related papers)
View all Related Experts
Fazel Shokri (15)
Mohammad Mehdi Amiri (14)
Other Related Docs
9. A Novel Anti-Her2 Bispecific Antibody With Potent Tumor Inhibitory Effects in Vitro and in Vivo, Frontiers in Immunology (2021)
10. The Role of Her2 Alterations in Clinicopathological and Molecular Characteristics of Breast Cancer and Her2-Targeted Therapies: A Comprehensive Review, Medical Oncology (2022)
11. Inhibitory Effect of Polyclonal Antibodies Against Her3 Extracellular Subdomains on Breast Cancer Cell Lines, Asian Pacific Journal of Cancer Prevention (2020)
12. Development of a Novel Inhibitory Chimeric Anti-Her2 Monoclonal Antibody, Iranian Journal of Immunology (2019)
13. Differential Tumor Inhibitory Effects Induced by Her3 Extracellular Subdomain-Specific Mouse Monoclonal Antibodies, Cancer Chemotherapy and Pharmacology (2022)
14. New Insights Into Affinity Proteins for Her2-Targeted Therapy: Beyond Trastuzumab, Biochimica et Biophysica Acta - Reviews on Cancer (2020)
15. Monoclonal Antibody-Based Therapeutics, Targeting the Epidermal Growth Factor Receptor Family: From Herceptin to Pan Her, Journal of Pharmacy and Pharmacology (2018)
16. Evaluation of the Anti-Tumor Effects of an Anti-Human Epidermal Growth Factor Receptor 2 (Her2) Monoclonal Antibody in Combination With Cd11b+/Gr-1+ Myeloid Cells Depletion Using a Recombinant Peptibody in 4 T1-Her2 Tumor Model, International Immunopharmacology (2023)
17. Preparation of Nanoliposomes Containing Her2/Neu (P5+435) Peptide and Evaluation of Their Immune Responses and Anti-Tumoral Effects As a Prophylactic Vaccine Against Breast Cancer, PLoS ONE (2020)
18. Clinical Perspective: Antibody-Drug Conjugates for the Treatment of Her2-Positive Breast Cancer, Molecular Therapy (2023)
19. Immune Checkpoint Inhibitors: Review of the Existing Evidence and Challenges in Breast Cancer, Immunotherapy (2021)
20. The Role of Oncomirs in the Pathogenesis and Treatment of Breast Cancer, Biomedicine and Pharmacotherapy (2016)
21. Recent Progress in Immunotherapy of Breast Cancer Targeting the Human Epidermal Growth Factor Receptor 2 (Her2), Journal of Oncology Pharmacy Practice (2021)
22. Application of E75 Peptide Vaccine in Breast Cancer Patients: A Systematic Review and Meta-Analysis, European Journal of Pharmacology (2018)
23. Gdnf Induces Ret–Src–Her2-Dependent Growth in Trastuzumab-Sensitive But Src-Independent Growth in Resistant Breast Tumor Cells, Breast Cancer Research and Treatment (2017)
24. A Novel Tumor Inhibitory Hybridoma Monoclonal Antibody With Dual Specificity for Her3 and Her2, Current Research in Translational Medicine (2021)
25. Potent Synergistic Anti-Tumor Activity of a Novel Humanized Anti-Her2 Antibody Hersintuzumab in Combination With Trastuzumab in Xenograft Models, Investigational New Drugs (2021)
26. Plant-Based Vaccines and Cancer Therapy: Where Are We Now and Where Are We Going?, Pharmacological Research (2021)
27. Comparison of Different Transient Gene Expression Systems for the Production of a New Humanized Anti-Her2 Monoclonal Antibody (Hersintuzumab), DARU# Journal of Pharmaceutical Sciences (2023)
28. Targeted Cancer Therapy Through Antibody Fragments-Decorated Nanomedicines, Journal of Controlled Release (2017)